- Home
- ZVRA vs ARVN Comparison
ZVRA vs ARVN Comparison
Compare ZVRA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVRA
- ARVN
- Stock Information
- Founded
- ZVRA 2006
- ARVN 2015
- Country
- ZVRA United States
- ARVN United States
- Employees
- ZVRA N/A
- ARVN N/A
- Industry
- ZVRA Biotechnology: Pharmaceutical Preparations
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- ZVRA Health Care
- ARVN Health Care
- Exchange
- ZVRA Nasdaq
- ARVN Nasdaq
- Market Cap
- ZVRA 467.6M
- ARVN 456.2M
- IPO Year
- ZVRA 2015
- ARVN 2018
- Fundamental
- Price
- ZVRA $7.33
- ARVN $7.98
- Analyst Decision
- ZVRA Strong Buy
- ARVN Buy
- Analyst Count
- ZVRA 10
- ARVN 22
- Target Price
- ZVRA $22.67
- ARVN $20.02
- AVG Volume (30 Days)
- ZVRA 1.3M
- ARVN 1.3M
- Earning Date
- ZVRA 11-11-2025
- ARVN 10-29-2025
- Dividend Yield
- ZVRA N/A
- ARVN N/A
- EPS Growth
- ZVRA N/A
- ARVN N/A
- EPS
- ZVRA N/A
- ARVN N/A
- Revenue
- ZVRA $62,020,000.00
- ARVN $372,800,000.00
- Revenue This Year
- ZVRA $329.57
- ARVN $1.61
- Revenue Next Year
- ZVRA $55.29
- ARVN N/A
- P/E Ratio
- ZVRA N/A
- ARVN N/A
- Revenue Growth
- ZVRA 161.81
- ARVN 299.57
- 52 Week Low
- ZVRA $6.19
- ARVN $5.90
- 52 Week High
- ZVRA $13.16
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- ZVRA 22.63
- ARVN 49.90
- Support Level
- ZVRA $8.65
- ARVN $7.58
- Resistance Level
- ZVRA $9.48
- ARVN $7.89
- Average True Range (ATR)
- ZVRA 0.39
- ARVN 0.37
- MACD
- ZVRA -0.11
- ARVN -0.03
- Stochastic Oscillator
- ZVRA 7.36
- ARVN 18.42
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.